Suppr超能文献

基于可切除性状态分层的胰腺导管腺癌患者腹腔灌洗液细胞学检查的预后价值。

Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status.

机构信息

Department of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Department of Advanced Medicine, Hiroshima University, Hiroshima, Japan.

出版信息

J Gastrointest Surg. 2021 Nov;25(11):2871-2880. doi: 10.1007/s11605-021-04978-3. Epub 2021 Mar 25.

Abstract

BACKGROUND

The prognostic value of peritoneal lavage cytology (CY) for pancreatic ductal adenocarcinoma (PDAC) remains controversial. We assessed the prognostic impact of CY status stratified by resectability in PDAC patients treated with surgical resection.

METHODS

Clinical data from 440 patients with PDAC who underwent surgical resection were retrospectively analyzed to examine the association of CY status with clinicopathological factors and survival.

RESULTS

Positive CY status (CY+) was found in 30 patients (7%). These patients had significantly worse overall survival in both the resectable (R) (P = 0.002) and borderline resectable (BR) (P < 0.001) groups. The median survival time of CY+ patients in the R and BR groups was 25.6 and 6.7 months, respectively. Multivariate analysis revealed that CY+ was an independent prognostic factor in the BR group (P < 0.001) but not in the R group (P = 0.08). In the R group, CY+ patients who received adjuvant chemotherapy had significantly longer overall survival than those without adjuvant chemotherapy (34.3 vs. 9.8 months, respectively; P < 0.001).

CONCLUSIONS

The prognosis of CY+ patients in the BR group was extremely poor. In the R group, surgical resection combined with adjuvant chemotherapy may improve the prognosis of CY+ patients.

摘要

背景

腹膜灌洗细胞学(CY)对胰腺导管腺癌(PDAC)的预后价值仍存在争议。我们评估了在接受手术切除治疗的 PDAC 患者中,根据可切除性对 CY 状态分层的预后影响。

方法

回顾性分析了 440 例接受手术切除的 PDAC 患者的临床资料,以检查 CY 状态与临床病理因素和生存的关系。

结果

30 例(7%)患者 CY 阳性(CY+)。CY+患者在可切除(R)(P=0.002)和交界可切除(BR)(P<0.001)组中的总生存率均显著降低。R 和 BR 组中 CY+患者的中位生存时间分别为 25.6 和 6.7 个月。多因素分析显示,CY+是 BR 组的独立预后因素(P<0.001),但不是 R 组的独立预后因素(P=0.08)。在 R 组中,接受辅助化疗的 CY+患者的总生存率明显长于未接受辅助化疗的患者(分别为 34.3 和 9.8 个月;P<0.001)。

结论

BR 组中 CY+患者的预后极差。在 R 组中,手术切除联合辅助化疗可能改善 CY+患者的预后。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验